IHI vs IYH

Key Takeaways

• IHI offers targeted exposure to U.S. medical devices manufacturers and distributors, tracking the Dow Jones U.S. Select Medical Equipment Index with 47 holdings, while IYH provides broader U.S. healthcare sector coverage via the Russell 1000 Health Care RIC 22.5/45 Capped Index with 103 holdings.
• Both ETFs share an identical expense ratio of 0.38%, ensuring cost parity for investors comparing long-term ownership.
• IHI's top holdings, such as ISRG and ABT, emphasize innovation-driven medical equipment firms; IYH features dominant pharma names like LLY and JNJ.
• IYH exhibits lower volatility with a 3-year beta of 0.54 versus IHI's 0.90, appealing to risk-averse investors seeking defensive healthcare positioning.
• Recent market cycles show IYH demonstrating greater relative stability amid sector rotations, while IHI faces higher sensitivity to medtech innovation cycles and supply chain dynamics.
• IHI's concentrated portfolio (top 10 ~75%) contrasts with IYH's more diversified top 10 (~57%), influencing risk profiles and performance drivers.

Introduction

Investors navigating the healthcare sector in today's environment of innovation acceleration and macroeconomic uncertainty often weigh targeted subsector plays against broader diversification. The iShares U.S. Medical Devices ETF (IHI) and iShares U.S. Healthcare ETF (IYH) represent complementary yet distinct strategies within this resilient asset class. IHI zeros in on medical equipment makers, capitalizing on technological advancements in devices and diagnostics. IYH, conversely, spans pharmaceuticals, biotechnology, providers, and equipment for comprehensive sector exposure. These ETFs appeal to those targeting healthcare's defensive qualities amid interest rate fluctuations and sector rotation trends, offering alternatives for thematic purity versus balanced risk in recent market cycles.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) is a passively managed fund seeking to replicate the Dow Jones U.S. Select Medical Equipment Index, comprising U.S. equities engaged in manufacturing and distributing medical devices like imaging scanners, prosthetics, and pacemakers. Launched in 2006, it holds 47 stocks with approximately $2.9 billion in assets under management (AUM). Its expense ratio stands at 0.38%.

Top holdings include leaders in robotic surgery and diagnostics: ISRG (Intuitive Surgical, ~17%), ABT (Abbott Laboratories, ~16%), and SYK (Stryker, ~11%). The portfolio is nearly 100% allocated to healthcare equipment, reflecting its thematic focus. With a P/E ratio around 30 and 3-year beta of 0.90, IHI suits investors betting on medtech growth but carries concentration risk from its top-heavy structure (top 10 holdings ~75%). Quarterly rebalancing aligns it closely with the benchmark.

iShares U.S. Healthcare ETF (IYH) Overview

The iShares U.S. Healthcare ETF (IYH), launched in 2000, tracks the Russell 1000 Health Care RIC 22.5/45 Capped Gross Index, providing diversified exposure to U.S. healthcare equities across pharmaceuticals, biotech, equipment, and providers. It manages about $2.8 billion in AUM with an expense ratio of 0.38% and 103 holdings.

Leading positions feature pharmaceutical giants: LLY (Eli Lilly, ~14%), JNJ (Johnson & Johnson, ~10%), ABBV (AbbVie, ~7%), and UNH (UnitedHealth Group, ~6%). Sector allocations include pharmaceuticals (36%), biotechnology (22%), health care equipment (17%), and managed health care (9%). A P/E of 25 and 3-year beta of 0.54 underscore its stability, with top 10 holdings comprising ~57% for balanced diversification. Capping limits single-stock dominance, enhancing structural resilience.

Industry and Thematic Backdrop

The healthcare sector endures as a defensive pillar amid economic volatility, propelled by aging demographics, AI integration in diagnostics, and rising demand for innovative therapies. Medical devices benefit from procedural growth in cardiology and robotics, alongside medtech M&A surges, though facing supply chain pressures and regulatory scrutiny on pricing. Broader healthcare sees capital flows favoring pharmaceuticals and biotech amid drug innovation pipelines, tempered by policy shifts like PBM (pharmacy benefit manager) reforms and reimbursement constraints. Recent cycles highlight resilience, with AI-driven efficiencies and home-based care expansion as catalysts, juxtaposed against cybersecurity risks and workforce shortages. Both subsectors navigate macroeconomic drivers like interest rates impacting growth stocks, positioning healthcare for steady inflows versus cyclical peers.

Performance and Positioning Comparison

In recent months, IYH has shown superior relative stability, with YTD declines around -5% versus IHI's steeper -14%, reflecting broader diversification buffering against medtech volatility. Over multi-year cycles, IYH's lower beta (0.54 vs. 0.90) has delivered steadier returns, less sensitive to interest rate hikes pressuring high-growth device makers. IHI's performance ties closely to innovation cycles in top holdings like ISRG, amplifying upside in procedural booms but heightening drawdowns during sector rotations toward value-oriented pharma. IYH benefits from earnings momentum in large-cap pharma amid biotech funding recovery, exhibiting lower standard deviation. Volatility differences underscore IHI's thematic beta versus IYH's sector-anchor role, with both navigating healthcare's defensive momentum amid macro shifts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes like healthcare ETFs. Explore it today to uncover hidden insights in real-time.

Tickeron AI Verdict

Tickeron’s AI currently favors IYH due to its superior diversification profile across 103 holdings, lower volatility (3-year beta 0.54), and consistent trend stability in recent market cycles. While IHI excels in targeted medtech exposure with structural innovation tailwinds, IYH's balanced sector allocations and cost efficiency position it probabilistically stronger for risk-adjusted returns amid uncertain macro environments and healthcare policy flux. This assessment prioritizes observable resilience over thematic concentration.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations